SHEP-002

SHEP-002 is a small molecule therapeutic currently in the IND-enabling and preclinical development stages, developed by Shepherd Therapeutics. It is being investigated for the treatment of several rare and underserved cancers, including adenoid cystic carcinoma, adrenocortical carcinoma, carcinoid tumors, cholangiocarcinoma, esophageal cancer, and Ewing's sarcoma. The drug was identified or developed using Shepherd's DELVE platform, which integrates multi-omic data and machine learning to identify therapeutic opportunities for rare oncology indications. While the specific molecular target of SHEP-002 has not been publicly disclosed, it represents a core asset in the company's pipeline focused on addressing the high unmet need in rare cancer populations.